JP2014523897A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523897A5
JP2014523897A5 JP2014517952A JP2014517952A JP2014523897A5 JP 2014523897 A5 JP2014523897 A5 JP 2014523897A5 JP 2014517952 A JP2014517952 A JP 2014517952A JP 2014517952 A JP2014517952 A JP 2014517952A JP 2014523897 A5 JP2014523897 A5 JP 2014523897A5
Authority
JP
Japan
Prior art keywords
phenyl
aminomethyl
ethoxy
ethyl
benzylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523897A (ja
JP5921679B2 (ja
Filing date
Publication date
Priority claimed from GB1111682.9A external-priority patent/GB2494851A/en
Application filed filed Critical
Publication of JP2014523897A publication Critical patent/JP2014523897A/ja
Publication of JP2014523897A5 publication Critical patent/JP2014523897A5/ja
Application granted granted Critical
Publication of JP5921679B2 publication Critical patent/JP5921679B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517952A 2011-07-07 2012-07-06 血漿カリクレインの阻害薬としてのベンジルアミン誘導体 Expired - Fee Related JP5921679B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161505305P 2011-07-07 2011-07-07
GB1111682.9 2011-07-07
GB1111682.9A GB2494851A (en) 2011-07-07 2011-07-07 Plasma kallikrein inhibitors
US61/505,305 2011-07-07
PCT/GB2012/051588 WO2013005045A1 (en) 2011-07-07 2012-07-06 Benzylamine derivatives as inhibitors of plasma kallikrein

Publications (3)

Publication Number Publication Date
JP2014523897A JP2014523897A (ja) 2014-09-18
JP2014523897A5 true JP2014523897A5 (enExample) 2015-08-20
JP5921679B2 JP5921679B2 (ja) 2016-05-24

Family

ID=44544412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517952A Expired - Fee Related JP5921679B2 (ja) 2011-07-07 2012-07-06 血漿カリクレインの阻害薬としてのベンジルアミン誘導体

Country Status (32)

Country Link
US (2) US9051249B2 (enExample)
EP (1) EP2729443B3 (enExample)
JP (1) JP5921679B2 (enExample)
KR (1) KR101999195B1 (enExample)
CN (1) CN103687846B (enExample)
AR (1) AR087102A1 (enExample)
AU (1) AU2012280064B2 (enExample)
BR (1) BR112014000240B1 (enExample)
CA (1) CA2841042C (enExample)
CL (1) CL2014000032A1 (enExample)
CO (1) CO6940413A2 (enExample)
CY (1) CY1117200T1 (enExample)
DK (1) DK2729443T6 (enExample)
ES (1) ES2560612T7 (enExample)
GB (1) GB2494851A (enExample)
HR (1) HRP20160101T4 (enExample)
HU (1) HUE027482T2 (enExample)
IL (1) IL230332A (enExample)
ME (1) ME02308B (enExample)
MX (1) MX343740B (enExample)
MY (1) MY185103A (enExample)
PH (1) PH12013502677A1 (enExample)
PL (1) PL2729443T6 (enExample)
PT (1) PT2729443E (enExample)
RS (1) RS54509B2 (enExample)
RU (1) RU2607045C2 (enExample)
SI (1) SI2729443T1 (enExample)
SM (1) SMT201600020B (enExample)
TW (1) TWI537238B (enExample)
UA (1) UA115427C2 (enExample)
WO (1) WO2013005045A1 (enExample)
ZA (1) ZA201400682B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2770989T (pt) 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
WO2015106200A2 (en) * 2014-01-10 2015-07-16 Cornell University Dipeptides as inhibitors of human immunoproteasomes
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
EP3362754B1 (en) 2015-10-15 2021-12-22 Cornell University Proteasome inhibitors and uses thereof
WO2017207983A1 (en) 2016-05-31 2017-12-07 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201713660D0 (en) * 2017-08-25 2017-10-11 Kalvista Pharmaceuticals Ltd Pharmaceutical compositions
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
JP7078722B2 (ja) 2017-11-29 2022-05-31 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレイン阻害剤を含む剤形
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN111217670B (zh) * 2018-11-25 2021-04-09 中国科学院大连化学物理研究所 一种催化还原化合物中羰基为亚甲基的方法
CN113474318A (zh) * 2019-04-22 2021-10-01 南京明德新药研发有限公司 用作血浆激肽释放酶抑制剂的双环烷类化合物
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
PH12022550124A1 (en) * 2019-08-21 2022-11-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
EP4116299A4 (en) 2020-03-04 2024-03-27 Medshine Discovery Inc. Heterocyclic compound
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2022079446A1 (en) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Treatments of angioedema
EP4232031A1 (en) 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
CA3255900A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited FORMULATIONS OF A PLASMA KALLICEREIN INHIBITOR
EP4673437A1 (en) 2023-02-27 2026-01-07 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor
WO2025153806A1 (en) 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
JPH11503161A (ja) * 1995-04-04 1999-03-23 メルク エンド カンパニー インコーポレーテッド トロンビン阻害剤
EP1364960A4 (en) * 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
DE102006050672A1 (de) * 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
EP2152664B1 (en) * 2007-06-13 2014-09-03 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
EP2265601B1 (en) 2008-03-13 2012-02-01 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
CA2783801A1 (en) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
AU2011210802B2 (en) * 2010-01-28 2014-10-16 The Medicines Company (Leipzig) Gmbh Trypsin-like serine protease inhibitors, and their preparation and use
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein

Similar Documents

Publication Publication Date Title
RU2014104226A (ru) Бензиламиновые производные как ингибиторы калликреина плазмы
JP2014502979A5 (enExample)
CN101636154B (zh) Task-1和task-3离子通道抑制剂
JP6306609B2 (ja) 医薬組成物
RU2486181C2 (ru) Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
JP2010533160A5 (enExample)
JP2007039461A5 (enExample)
JP2011529037A5 (enExample)
JP2020530475A5 (enExample)
JP7159302B2 (ja) 線維性疾患の治療のための方法
RU2015142383A (ru) Новейшие антагонисты trpa1-рецепторов
RU2007119427A (ru) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
JP2013040215A (ja) 安定な乳化組成物
JP2003535844A5 (enExample)
JP2017509694A5 (enExample)
JP6957459B2 (ja) ニトロキシルドナーとしてのn−ヒドロキシルスルホンアミド誘導体
JP2011519832A5 (enExample)
JP2015131865A (ja) 抗癌用医薬
KR101422299B1 (ko) (2r)-2-〔(4-설포닐)아미노페닐〕프로판아마이드 및 이들 화합물을 함유하는 약학 조성물
JP2020530475A (ja) 医薬組成物
JP2011524362A5 (enExample)
WO2002045750A1 (en) Combination drugs
US20100029719A1 (en) Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
JP2018520145A5 (enExample)
KR20100072008A (ko) 섬유증을 치료하기 위한 피페리디닐아미노-티에노[2,3-d]피리미딘 화합물